Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam siRNA Upheld by German Patent Office

Premium

Alnylam Pharmaceuticals said last week that the German patent office has upheld the company's Kreutzer-Limmer patent in oral proceedings held before the office's opposition board.

The patent, DE 10066235, was granted in January 2008, and covers methods, uses, and medicaments of siRNAs, with a length between 15 and 49 nucleotides, expressed through a vector, according to Alnylam.

Additionally, the patent office rejected a request by Silence Therapeutics, Pfizer, and Sanofi-Aventis, which has opposed the patent, to revoke the intellectual property, the company said.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.